Evidence map›Paper›PMID 25778696›Full record

ArticleUrologic oncology2015

Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?

Reza Mehrazin, Marc C Smaldone, Brian Egleston, Jeffrey J Tomaszewski, Charles W Concodora, Timothy K Ito, Philip H Abbosh, David Y T Chen, Alexander Kutikov, Robert G Uzzo

Open access · greenAbstract read
In one paragraph

Article in Urologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Reza MehrazinDepartment of Urology & Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY.
Marc C SmaldoneDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Brian EglestonBiostatistics & Bioinformatics Facility, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Jeffrey J TomaszewskiDepartment of Surgery, MD Anderson Cancer Center at Cooper, Rowan, University School of Medicine, Camden, NJ.
Charles W ConcodoraDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Timothy K ItoDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Philip H AbboshDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
David Y T ChenDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Alexander KutikovDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA.
Robert G UzzoDepartment of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA. Electronic address: Robert.Uzzo@fccc.edu.
Temple University Health System · USFox Chase Cancer Center · USIcahn School of Medicine at Mount Sinai · USThe University of Texas MD Anderson Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

introductionLinear growth rate (LGR) is the most commonly employed trigger for definitive intervention in patients with renal masses managed with an initial period of active surveillance (AS). Using our institutional cohort, we explored the association between tumor anatomic complexity at presentation and LGR in patients managed with AS. METHODS AND MATERIALS: Enhancing renal masses managed expectantly for at least 6 months were included for analysis. The association between Nephrometry Score and LGR was assessed using generalized estimating equations, adjusting for the age, Charlson score, race, sex, and initial tumor size.

resultsOverall, 346 patients (401 masses) met the inclusion criteria (18% ≥ cT1b), with a median follow-up of 37 months (range: 6-169). Of these, 44% patients showed progression to definitive intervention with a median duration of 27 months (range: 6-130). On comparing patients managed expectantly to those requiring intervention, no difference was seen in median tumor size at presentation (2.2 vs. 2.2 cm), whereas significant differences in median age (74 vs. 65 y, P < 0.001), Charlson comorbidity score (3 vs. 2, P<0.001), and average LGR (0.23 vs. 0.49 cm/y, P < 0.001) were observed between groups. Following adjustment, for each 1-point increase in Nephrometry Score sum, the average tumor LGR increased by 0.037 cm/y (P = 0.002). Of the entire cohort, 6 patients (1.7%) showed progression to metastatic disease.

conclusionsThe demonstrated association between anatomic tumor complexity at presentation and renal masses of LGR of clinical stage 1 under AS may afford a clinically useful cue to tailor individual patient radiographic surveillance schedules and warrants further evaluation.

Indexed as

Watchful WaitingAgedCarcinoma, Renal CellCohort StudiesDisease ProgressionFemaleHumansKidney NeoplasmsMaleMiddle AgedActive surveillanceGrowth kineticsNephrometry ScoreRenal cell carcinomaRenal tumorTumor complexity

Identifiers

PMID25778696
PMCPMC4417444
OpenAlexW1965295880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.